Navelbine (Vinorelbine Tartrate)

Vinorelbine Tartrate interferes with microtubule assembly by binding to tubulin, a key protein required for cell division. This prevents the formation of the mitotic spindle, arrests cancer cells in the M phase of the cell cycle, and ultimately triggers programmed cell death of rapidly proliferating tumour cells.

The exact dose of Navelbine is determined by the prescribing oncologist based on individual factors such as cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. Healthcare professionals adjust the regimen to achieve optimal therapeutic effect while managing safety.

Safety data for Vinorelbine Tartrate in pregnancy and lactation are limited. Because the drug may cause fetal harm and is excreted in breast milk, it is generally contraindicated in pregnant or nursing women unless the potential benefit outweighs the risk, as assessed by a qualified physician.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Navelbine belongs to the Vinca alkaloid class, which differs from taxanes or anthracyclines in its mechanism of disrupting microtubule formation. Compared with some alternatives, Vinorelbine often shows a distinct toxicity profile, with relatively lower rates of alopecia but higher incidences of neutropenia and pulmonary effects, influencing treatment selection.

Navelbine tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Navelbine is taken orally with a full glass of water, usually on an empty stomach unless instructed otherwise by the prescriber. The dose is swallowed whole; it should not be crushed, chewed, or dissolved unless a specific formulation permits such handling.

The most critical risks include severe neutropenia that can lead to life‑threatening infections, pulmonary toxicity such as interstitial pneumonitis, and rare but serious allergic reactions. Patients should promptly report fever, persistent cough, shortness of breath, or any signs of an allergic response to their healthcare provider.

Navelbine is contraindicated in patients with known hypersensitivity to Vinorelbine or any Vinca alkaloid, those with severe bone‑marrow suppression, uncontrolled infections, or significant pre‑existing pulmonary disease. It should also be avoided in pregnant or nursing women unless absolutely necessary.